AstraZeneca PLC (AZN)vsStrata Critical Medical, Inc. (SRTA)
AZN
AstraZeneca PLC
$158.75
-0.16%
HEALTHCARE · Cap: $263.09B
SRTA
Strata Critical Medical, Inc.
$6.03
0.00%
HEALTHCARE · Cap: $446.48M
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 26747% more annual revenue ($61.37B vs $228.58M). SRTA leads profitability with a 20.6% profit margin vs 17.0%. AZN earns a higher WallStSmart Score of 60/100 (C+).
AZN
Buy60
out of 100
Grade: C+
SRTA
Buy52
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+19.3%
Fair Value
$196.68
Current Price
$158.75
$37.93 discount
Intrinsic value data unavailable for SRTA.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 21 in profit
Strong operational efficiency at 23.5%
Generating 2.1B in free cash flow
Revenue surging 87.4% year-over-year
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Keeps 21 of every $100 in revenue as profit
Reasonable price relative to book value
Areas to Watch
Moderate valuation
2.5% earnings growth
Distress zone — elevated risk
0.0% earnings growth
Smaller company, higher risk/reward
Weak financial health signals
Negative free cash flow — burning cash
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.0% and operating margin at 23.5%. PEG of 1.47 suggests the stock is reasonably priced for its growth.
Bull Case : SRTA
The strongest argument for SRTA centers on Revenue Growth, Debt/Equity, Altman Z-Score. Profitability is solid with margins at 20.6% and operating margin at -2.8%. Revenue growth of 87.4% demonstrates continued momentum.
Bear Case : AZN
The primary concerns for AZN are P/E Ratio, EPS Growth, Altman Z-Score.
Bear Case : SRTA
The primary concerns for SRTA are EPS Growth, Market Cap, Piotroski F-Score.
Key Dynamics to Monitor
AZN profiles as a mature stock while SRTA is a growth play — different risk/reward profiles.
SRTA carries more volatility with a beta of 2.22 — expect wider price swings.
SRTA is growing revenue faster at 87.4% — sustainability is the question.
AZN generates stronger free cash flow (2.1B), providing more financial flexibility.
Bottom Line
AZN scores higher overall (60/100 vs 52/100), backed by strong 17.0% margins. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
Strata Critical Medical, Inc.
HEALTHCARE · MEDICAL CARE FACILITIES · USA
Strata Critical Medical, Inc. provides time critical logistics solutions and specialized medical services to healthcare providers across the United States. The company is headquartered in New York, New York.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?